Clinical features and treatment of 70 children with lupus anticoagulant-hypoprothrombinemia syndrome: a retrospective study from a single center in China

• Published in: Research and practice in thrombosis and haemostasis Vol. 8; no. 7; p. 102577
• Main Authors: Tian, Dandan, Zhang, Junfeng, Lou, Jintu, Chen, Xuejun, Liang, Juan, Xu, Xiaojun, Gao, Hui, Nie, Wenjian, Ye, Qing, Shen, Hongqiang
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2024; Elsevier
• Subjects: autoimmune diseases; children; hypoprothrombinemia; infection; lupus anticoagulant (LA); Original; autoimmune diseases; infection; hypoprothrombinemia; lupus anticoagulant (LA); children
• ISSN: 2475-0379; 2475-0379
• DOI: 10.1016/j.rpth.2024.102577

Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disorder characterized by the presence of lupus anticoagulant (LA) and acquired hypoprothrombinemia. To summarize the experience of diagnosis, clinical features, and treatment of lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS). A retrospective study of 70 children diagnosed with LAHPS from January 2019 to February 2024 at a single center was conducted. A total of 70 subjects (32 boys and 38 girls), with a mean age of 5.58 years, were included in the study. Among these subjects, 15 had autoimmune diseases (AIDs), 51 had infections, and 4 had unknown causes. Fifty-six of 70 (80%) subjects experienced bleeding with the median bleeding score of 4, 1 of 70 (1.4%) presented with thrombosis, and 13 of 70 (18.6%) were asymptomatic. All patients exhibited prolonged prothrombin time, significantly prolonged activated partial thromboplastin time, decreased factor (F)II activity (FII:C), and positive lupus anticoagulant. There was a weak negative correlation between the severity of bleeding and FII:C level (rs = −0.4283; P < .001). Patients with infection-associated LAHPS were younger than those with AIDs-associated LAHPS (P < .0001). In the study, LAHPS subjects are treated with corticosteroids as the first-line therapy, or in combination with immunosuppressants. Coagulation factor replacement therapy can effectively prevent and control bleeding events. After follow-up, lupus anticoagulant of all patients had turned negative within 12 weeks. And, prothrombin time and FII:C were completely normalized of all patients without recurrence of bleeding and without thrombosis. Children develop LAHPS most commonly after AIDs and infection. Most patients presented with mild to moderate bleeding. The severity of bleeding symptoms was not exactly parallel to the decreased FII:C level. •Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is a rare acquired bleeding disease.•We analyzed the clinical data of 70 patients with LAHPS from a single center.•Most patients with LAHPS presented with mild to moderate bleeding.•The severity of bleeding symptoms was not exactly parallel to the decreased FII:C level.